Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.

Roczniki Akademii Medycznej w Bialymstoku (1995) Pub Date : 2005-01-01

A M Kuklińska, W J Musiał, K A Kamiński, P Kralisz, W Modrzejewski, B Sobkowicz, S Dobrzycki, S Stec, I Wojtkowska

{"title":"Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.","authors":"A M Kuklińska, W J Musiał, K A Kamiński, P Kralisz, W Modrzejewski, B Sobkowicz, S Dobrzycki, S Stec, I Wojtkowska","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the influence of low dose rofecoxib on inflammatory mediators and prostacyclin synthesis in patients with acute coronary syndromes (ACS) in a short-term follow up.Material and methods: Twenty nine patients with ACS without ST elevation were randomized to simvastatin alone or together with low dose rofecoxib. Serum levels of interleukin 6 (IL-6), 6-keto-PGF-1alpha--stable product of prostacyclin (PGT2) and hs-C-reactive protein (hs-CRP) were assessed on enrollment and after 30-day follow up.Results: Combination of rofecoxib with statin significantly decreased levels of hs-CRP after one month therapy (5.21 mg/l +/- 4.12 vs 2.11 mg/l +/- 2.1; p=0.0092). This effect was not evident in a group on statin alone (3.95 mg/l +/- 3.33 vs 2.48 mg/l +/- 2.39; p=0.31). 6-keto-PGF-1alpha increased not significantly in both groups. IL-6 concentration has not changed during follow up.Conclusions: Low dose of selective COX-2 inhibitor exerts significant anti-inflammatory effect and does not diminish PG12 synthesis in study group of patients with ACS.","PeriodicalId":79372,"journal":{"name":"Roczniki Akademii Medycznej w Bialymstoku (1995)","volume":"50 ","pages":"339-42"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Roczniki Akademii Medycznej w Bialymstoku (1995)","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the influence of low dose rofecoxib on inflammatory mediators and prostacyclin synthesis in patients with acute coronary syndromes (ACS) in a short-term follow up.

Material and methods: Twenty nine patients with ACS without ST elevation were randomized to simvastatin alone or together with low dose rofecoxib. Serum levels of interleukin 6 (IL-6), 6-keto-PGF-1alpha--stable product of prostacyclin (PGT2) and hs-C-reactive protein (hs-CRP) were assessed on enrollment and after 30-day follow up.

Results: Combination of rofecoxib with statin significantly decreased levels of hs-CRP after one month therapy (5.21 mg/l +/- 4.12 vs 2.11 mg/l +/- 2.1; p=0.0092). This effect was not evident in a group on statin alone (3.95 mg/l +/- 3.33 vs 2.48 mg/l +/- 2.39; p=0.31). 6-keto-PGF-1alpha increased not significantly in both groups. IL-6 concentration has not changed during follow up.

Conclusions: Low dose of selective COX-2 inhibitor exerts significant anti-inflammatory effect and does not diminish PG12 synthesis in study group of patients with ACS.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

低剂量罗非昔布、炎症和前列环素在急性冠脉综合征中的合成。

目的:评价低剂量罗非昔布对急性冠脉综合征(ACS)患者炎症介质和前列环素合成的影响。材料与方法:29例无ST段抬高的ACS患者随机接受辛伐他汀单用或低剂量罗非昔布联合治疗。在入组时和随访30天后评估血清白细胞介素6 (IL-6)、6-酮- pgf -1 α——前列环素(PGT2)稳定产物和hs- c反应蛋白(hs-CRP)水平。结果:罗非昔布联合他汀治疗1个月后显著降低hs-CRP水平(5.21 mg/l +/- 4.12 vs 2.11 mg/l +/- 2.1;p = 0.0092)。这种影响在单独使用他汀类药物的组中不明显(3.95 mg/l +/- 3.33 vs 2.48 mg/l +/- 2.39;p = 0.31)。6-酮- pgf -1 α在两组均无明显升高。随访期间IL-6浓度无变化。结论:低剂量选择性COX-2抑制剂对ACS患者具有明显的抗炎作用，且不影响PG12的合成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Roczniki Akademii Medycznej w Bialymstoku (1995)

自引率

0.00%

发文量

期刊最新文献

The cortical evoked potentials in children with developmental coordination disorder (DCD). Neuroprotection possibilities in epileptic children. New antiepileptic drugs--an overview. Youth's knowledge and attitude to epilepsy. Community nursing care of the elderly during transformation of the primary health care system.